In Vitro: The synthetic pm26TGF-β1 peptide (1 μM, 10 μM and 100 μM; 24-48 hours) tested in peripheral blood mononuclear cells (PBMC) significantly down-modulates TNF-α and up-regulates IL-10 responses in an inflammatory microenvironment, leading to regulatory T cells (Treg) phenotype differentiation.
In Vivo: pm26TGF-β1 peptide (100-1000 µg/kg; subcutaneous injection; once; male C57BL/6 mice) treatment decreases neutrophils migration during inflammatory process in C57BL/6 mice.